NASDAQ:ALLO

Allogene Therapeutics, Inc Earning Date

USA |NASDAQ |USD

ALLO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 2, 2021 Sep 2021 $-0.56 $-0.53 $-0.52
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 2, 2021 Sep 2021 $10.00K $44.00K $0.00

Allogene Therapeutics, Inc's next earnings date is Tuesday, Nov 2, 2021 for the fiscal quarter ending Sep 2021.

ALLO Earnings Date & History Chart

ALLO Earnings & Revenue Forecast

ALLO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 18 $-0.59 $-0.72 $-0.50
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 16 $-1.92 $-2.19 $-1.58
Dec 2022 18 $-2.53 $-3.26 $-2.15

ALLO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.59 $-0.59 $-0.60
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-1.92 $-1.92 $-1.97
Dec 2022 2 / 1 $-2.55 $-2.55 $-2.57

ALLO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 16 $10.00K $0.00 $200.00K
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 17 $38.37M $38.00M $38.79M
Dec 2022 18 $2.22M $0.00 $39.40M

ALLO Earnings Date & Revenue History

ALLO Earnings History

|
Show More
Show More

ALLO Revenue History

|
Show More
Show More

Allogene Therapeutics, Inc Next Earnings Date & Report

ALLO Next Earnings Date & Report Preview: Sep 2021 (FQ)

ALLO's next earnings date is Tuesday, Nov 2, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 18 analysts, the average EPS estimation for Allogene Therapeutics, Inc's next quarterly earnings is $-0.56, with a low EPS estimation of $-0.62, and a high estimation of $-0.49.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $-0.55, the last 2 month trend is $-0.55, and the 3 month trend is $-0.57.

Based on 16 analysts, the average revenue estimation is $10.00K, with a low revenue estimation of $0.00, and a high estimation of $200.00K.

Allogene Therapeutics, Inc Previous Earnings Dates & Reports

ALLO Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Allogene Therapeutics, Inc's previous earnings date was Aug 4, 2021 for its fiscal quarter ended Jun 30, 2021.

ALLO's earnings per share (EPS) was $-0.53, beating the consensus analysts forecast of $-0.54 by 2.38%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 112.00%, and higher than the same period a year before (Jun 2020) by 0.00%.

Revenues were $44.00K.

The company reported a net income of $-70.94M.

Free cash flow for the quarter was $-52.07M , compared to $-55.79M last quarter and $-42.77M a year before.

ALLO ended the quarter with $51.21M in total debt, a decrease of -0.81% compared to the previous quarter, and an increase of 0.28% compared to the same quarter a year before.

ALLO Previous Earnings Date & Report Recap: Dec 2020 (FY)

Allogene Therapeutics, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

ALLO's earnings per share (EPS) was $-2.08, beating the consensus analysts forecast of $-2.11 by -1.42% , and lower than the previous year's EPS (Dec 2019) by 14.92%.

Revenues were $0.00.

The company reported a net income of $-250.22M.

Allogene Therapeutics, Inc reported a free cash flow of $-181.05M for its fiscal year, compared to $-188.14M a year ago.

The company ended the fiscal year with $53.78M in total debt, an increase of 4.74% compared to the previous year.